<DOC>
	<DOC>NCT00956410</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's disease.</brief_summary>
	<brief_title>To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients who have completed the Core study with no significant safety concerns Diagnosis of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression). Diagnosis or presence of an active, uncontrolled seizure disorder and/or cerebrovascular disease. diagnosis or presence of an active autoimmune and/or with an acute or chronic inflammation.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Active immunization</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Neurodegenerative diseases</keyword>
	<keyword>Vaccine</keyword>
</DOC>